In the Spotlight...

Impaired development of memory B cells and antibody responses in humans and mice deficient in PD-1 signaling

Ogishi and Kitaoka et al. demonstrated that the PD-1/PD-L1 axis was essential for optimal humoral immunity through T cell-dependent and B cell-intrinsic mechanisms. Patients with PD-1 or PD-L1 deficie...

IL-12 drives the expression of the inhibitory receptor NKG2A on human tumor-reactive CD8 T cells

Fesneau et al. showed that in HNSCC and CRC tumors, expression of the inhibitor NKG2A, a receptor for HLA-E that is associated with poor prognosis for many solid cancers, was upregulated upon differen...

IL-2/anti-IL-2 antibody complexes augment immune responses to therapeutic cancer vaccines

An effective scaffold-based vaccine (Vax) promoted massive and preferential monocyte expansion in the LNs. Addition of IL-2/anti-IL-2 (IL-2cx) significantly improved LN cDC1 expansion and activation w...

Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response

Guégan et al. analyzed tumor samples from 166 lung adenocarcinoma patients treated with immune checkpoint inhibitors (ICI) to evaluate the predictive value of CD8+ T cell exhaustion on responsiveness ...

Previous Digests

A tetraspecific NK cell engager armed with IL-2v targets B-NHL

November 27, 2024

To capitalize on the antitumor potential of NK cells for the treatment of B cell non-Hodgkin lymphoma (B-NHL), Demaria et al. developed a clinical-grade tetraspecific NK cell engager (NKCE) that targets NKp46 and CD16a on NK cells and CD2...

SITC - 39th Annual Meeting 2024

November 20, 2024

This week’s extensive special feature covers select talks from the SITC - 39th Annual Meeting 2024 in Houston, TX. We have organized the content by topics below. Keynote lectureRafi Ahmed Harnessing innate immunityEric VivierNicholas Huntington Cancer vaccinesElizabeth M. JaffeeCathy...

Novel vaccine strategy uses bacteria to deliver cancer neoantigens

November 13, 2024

In cancer immunotherapy, vaccination with tumor-specific neoantigens can be an effective way to induce antitumor immunity. In recent work, Redenti and Im et al. developed a novel system to deliver neoantigens using an engineered probiotic E. coli Nissle 191...

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ed Fritsch

Ute Burkhardt

Ute Burkhardt

Lauren Hitchings

Lauren Hitchings

Gaelle Llambi

Gaelle Llambi

Maartje Wouters

Maartje Wouters

Alex Najibi

Alex Najibi

Katherine J. Turner

Katherine J. Turner

Stan Wolf

Stan Wolf

Paula Hochman

Paula Hochman

Shishir Pant

Shishir Pant

Nathan Suek

Nathan Suek

Morgan Janes

Morgan Janes

Current Sponsors

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.